Concepedia

Kapil Vashisht

KV

Statistics

Publications

4

Citations

147

H-Index

4

Active since

2011

Affiliations

Sarah Cannon(Current)

Kapil Vashisht is an author at Sarah Cannon specializing in oncology, medicine, and cancer pharmacology.

Publications per year

2011–2021

4

Publications

4

Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide

Johann S. de Bono, Mark T. Fleming, Judy S. Wang et al. · Clinical Cancer Research · 2021 · 51 citations · Full text

Medicine, Oncology, Pharmacology +17

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

Song Cho, Francesca Zammarchi, David G. Williams et al. · Molecular Cancer Therapeutics · 2018 · 47 citations

Medicine, Oncology, Pharmacology +17

Role of genetic polymorphisms of CYP1A1, CYP3A5, CYP2C9, CYP2D6, and PON1 in the modulation of DNA damage in workers occupationally exposed to organophosphate pesticides

Satyender Singh, Vivek Kumar, Kapil Vashisht et al. · Toxicology and Applied Pharmacology · 2011 · 35 citations

Pharmacy, Genetics, Toxicology +14

High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy

Katharina Wiedemeyer, Martin Köbel, Holly Koelkebeck et al. · Human Pathology · 2020 · 14 citations

Medicine, Oncology, Pathology +15

1–4 of 4